Ophthalmology

Horizon Eye Specialists & LASIK Center Now Offers the First and Only FDA-Approved Trifocal Lens Implant for Cataract Surgery: AcrySof IQ PanOptix

Retrieved on: 
Tuesday, October 15, 2019
Medicine, Medical specialties, Ophthalmology, Vision, Eye surgery, Eye, Corrective lenses, LASIK, Cataract surgery, Cataract, Intraocular lens, Laser blended vision

SCOTTSDALE, Ariz., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Horizon Eye Specialists & Lasik Center , the leading comprehensive eye care center in Arizona, today announces it has started offering the latest generation in multifocal implants, the AcrySof IQ PanOptix lens by Alcon.

Key Points: 
  • SCOTTSDALE, Ariz., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Horizon Eye Specialists & Lasik Center , the leading comprehensive eye care center in Arizona, today announces it has started offering the latest generation in multifocal implants, the AcrySof IQ PanOptix lens by Alcon.
  • Similar to cataract surgery, this elective procedure is called Refractive Lens Exchange and is also performed at Horizon Eye Specialists.
  • Horizon Eye Specialists & LASIK Center has been offering comprehensive eye care since 1983.
  • The eye care center specializes in a full range of services, including CustomVue LASIK, cataract surgery, multifocal IOLs and much more.

Lineage Cell Therapeutics Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting

Retrieved on: 
Monday, October 14, 2019
Stem cells, Biotechnology, Pharmaceutical, Optical, Health, Medical devices, Clinical trials, Other Health, Vision, Perception, Senses, Ophthalmology, Optometry, Macular degeneration, RTT, Senescence, Visual acuity

The results were presented at the 2019 American Academy of Ophthalmology Annual Meeting (AAO 2019) in San Francisco, CA on October 14th, 2019.

Key Points: 
  • The results were presented at the 2019 American Academy of Ophthalmology Annual Meeting (AAO 2019) in San Francisco, CA on October 14th, 2019.
  • Overall, OpRegen appears well tolerated with preliminary evidence of improved structural changes and potential improvement in visual acuity following treatment in some patients.
  • We are encouraged by the interim data we have obtained so far from our clinical trial of OpRegen for dry AMD.
  • Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.

New to RX-Safety Oakley Prescription Safety Glasses and Sunglasses By Phillips Safety Research

Retrieved on: 
Sunday, October 13, 2019
Eyewear, Ophthalmology, Protective gear, Equipment, Glasses, Sports equipment, Medicine, Health, Medical prescription, Sunglasses

You should wear safety glasses anytime you're exposing your eyes to debris or potential hazards.

Key Points: 
  • You should wear safety glasses anytime you're exposing your eyes to debris or potential hazards.
  • Prescription Motorcycle Glasses - A pair of standard prescription glasses won't protect your eyes from impact, wind, or debris the way a pair of motorcycle glasses will.
  • A pair of prescription motorcycle glasses will keep your eyes fully protected and meet your prescription glasses requirements.
  • You can contact our experts here with questions about what kind of prescription safety glasses will work for you.

ZEISS showcases next-level eye care digitalization at AAO 2019

Retrieved on: 
Saturday, October 12, 2019
Carl Zeiss AG, Ophthalmology, Glaucoma, Optics, Health, Economy of Germany

SAN FRANCISCO, Oct. 12, 2019 /PRNewswire/ -- At the Annual Meeting of the American Academy of Ophthalmology (AAO) in San Francisco, ZEISS Medical Technology Segment will present the latest in digital eye care innovation and high-resolution imaging from October 12 15, 2019.

Key Points: 
  • SAN FRANCISCO, Oct. 12, 2019 /PRNewswire/ -- At the Annual Meeting of the American Academy of Ophthalmology (AAO) in San Francisco, ZEISS Medical Technology Segment will present the latest in digital eye care innovation and high-resolution imaging from October 12 15, 2019.
  • With the Integrated Diagnostic Imaging platform, ZEISS creates the ideal digital workflow using solutions like the CIRRUS 6000 and the ZEISS Glaucoma Workplace.
  • The ZEISS CIRRUS 6000, the next generation, ultra-fast 100kHz system, promises to dramatically elevate the efficiency of busy, advanced care practices.
  • ZEISS will showcase the latest solutions for digital eye care in Booth # 5669 in North Hall at the Annual Meeting of the American Academy of Ophthalmology (AAO) from October 12-15, 2019.

ZEISS showcases next-level eye care digitalization at AAO 2019

Retrieved on: 
Saturday, October 12, 2019
Carl Zeiss AG, Zeiss, Ophthalmology, Optics, Economy of Germany, Companies

With the vision and the expertise to bring digital technology to the next level, ZEISS is helping doctors provide their patients with transformational care.

Key Points: 
  • With the vision and the expertise to bring digital technology to the next level, ZEISS is helping doctors provide their patients with transformational care.
  • With the Integrated Diagnostic Imaging platform, ZEISS creates the ideal digital workflow using solutions like the CIRRUS 6000 and the ZEISS Glaucoma Workplace.
  • The ZEISS CIRRUS 6000, the next generation, ultra-fast 100kHz system, promises to dramatically elevate the efficiency of busy, advanced care practices.
  • ZEISS will showcase the latest solutions for digital eye care in Booth # 5669 in North Hall at the Annual Meeting of the American Academy of Ophthalmology (AAO) from October 12-15, 2019.

Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration

Retrieved on: 
Saturday, October 12, 2019
Medicine, Clinical medicine, Ophthalmology, Breakthrough therapy, Genentech, Ranibizumab, Macular degeneration, Retina, Intravitreal administration, Vascular endothelial growth factor, Anti–vascular endothelial growth factor therapy, Macular edema

In the second year of these studies, four injections of Abicipar resulted in the maintenance of visual gains comparable to monthly ranibizumab.

Key Points: 
  • In the second year of these studies, four injections of Abicipar resulted in the maintenance of visual gains comparable to monthly ranibizumab.
  • Through week 104, patients received Abicipar 2 mg every 8-weeks or every 12-weeks or ranibizumab 0.5 mg every 4 weeks.
  • At week 104 in the pooled Phase 3 data, the proportion of patients with stable vision was 93%, 90% and 94% in 8-week Abicipar; 12-week Abicipar and 4-week ranibizumab treatment regimens, respectively.
  • "Current anti-VEGF treatments for neovascular age-related macular degeneration require frequent intravitreal injections," said Rahul N. Khurana, M.D., Northern California Retina Vitreous Associates Medical Group.

Intelligent Retinal Imaging Systems (IRIS) Partners with Remidio Innovative Solutions Pvt Ltd to Provide Affordable Early Detection Systems for Diabetic Eye Disease

Retrieved on: 
Thursday, October 10, 2019
Ophthalmology, Optometry, Vision, Eye care, Medical specialties, Diabetes, Fundus photography, Teleophthalmology, Retinography

PENSACOLA, Fla., Oct. 10, 2019 /PRNewswire/ -- Intelligent Retinal Imaging Systems, Inc. (IRIS), the industry leader in telemedicine solutions for diabetic retinal disease, today announced a partnership with Remidio Innovative Solutions Pvt Ltd to bring their innovative smartphone based non mydriatic fundus camera to the U.S. market.

Key Points: 
  • PENSACOLA, Fla., Oct. 10, 2019 /PRNewswire/ -- Intelligent Retinal Imaging Systems, Inc. (IRIS), the industry leader in telemedicine solutions for diabetic retinal disease, today announced a partnership with Remidio Innovative Solutions Pvt Ltd to bring their innovative smartphone based non mydriatic fundus camera to the U.S. market.
  • "The Remidio device is portable, affordable and takes high quality images, which supported by the IRIS algorithms will make it much easier to provide sight-saving exams to patients with diabetes."
  • The Remidio portable, smartphone based fundus cameras have been validated against high-end desktop imaging systems, in peer reviewed publications in PLOSOne, Nature Eye, Ophthalmology Retina, JAMA Ophthalmology, to name a few.
  • Remidio's FDA 510k approved retinal imaging devices have screened more than 7.5 million patients, impacting the delivery of eye care in 15 countries globally.

Vantage EyeCare, LLC at 2019 American Academy of Ophthalmology Annual Meeting

Retrieved on: 
Thursday, October 10, 2019
Ophthalmology, Ophthalmic

PHILADELPHIA, Oct. 10, 2019 /PRNewswire/ -- The physicians and surgeons of Vantage EyeCare, LLC will be out in force at the American Academy of Ophthalmology's Annual Meeting in San Francisco, October 11 15, 2019, sharing their expertise and learning from their peers.

Key Points: 
  • PHILADELPHIA, Oct. 10, 2019 /PRNewswire/ -- The physicians and surgeons of Vantage EyeCare, LLC will be out in force at the American Academy of Ophthalmology's Annual Meeting in San Francisco, October 11 15, 2019, sharing their expertise and learning from their peers.
  • They join 16,000 ophthalmic professionals for the world's largest ophthalmic congress.
  • "Vantage EyeCare physicians are thought leaders, innovators, and national experts in their fields," says Julia Lee, CEO.
  • Additionally, as the largest ophthalmology practice in the country entirely physician-owned and operated, there continues to be great interest in our business model," explains Ms. Lee.

Lasik and Cataract Surgery Experts Featured at Trusted LASIK Surgeons Will Be Contributing to the 2019 Annual Meeting of the American Academy of Ophthalmology

Retrieved on: 
Thursday, October 10, 2019
Medical specialties, Health, Medicine, LASIK, Eye surgery, Ophthalmology, Surgeon, Cataract, LASIK MD, Avi Wallerstein

SAN FRANCISCO, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Trusted LASIK Surgeons, a premier online directory of LASIK, cataract and vision correction expert eye surgeons is pleased to announce that several members of its Trusted LASIK Surgeons and Trusted Cataract Surgeons Directories will be actively participating at the 2019 Annual Meeting of the American Academy of Ophthalmology (AAO).

Key Points: 
  • SAN FRANCISCO, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Trusted LASIK Surgeons, a premier online directory of LASIK, cataract and vision correction expert eye surgeons is pleased to announce that several members of its Trusted LASIK Surgeons and Trusted Cataract Surgeons Directories will be actively participating at the 2019 Annual Meeting of the American Academy of Ophthalmology (AAO).
  • For more details about each surgeons contributions to the 2019 meeting please visit our Trusted LASIK Surgeons Blog , Trusted LASIK Surgeons Facebook and Trusted LASIK Surgeons LinkedIn pages.
  • The Trusted LASIK Surgeons and Trusted Cataract Surgeons directories feature vision correction surgeons who are among the best and most qualified within in the United States.
  • To locate an expert LASIK, cataract, or and vision correction surgeon near you, please visitour Trusted LASIK Surgeons Directory or our Trusted Cataract Surgeons Directory .

American BriVision Announces Vitargus® Presentation at Upcoming AAO 2019 Annual Meeting

Retrieved on: 
Thursday, October 10, 2019
Ophthalmology, Specialty, Hematology

Company to initiate multi-national, multi-site pivotal study for Vitargus in 2020, assuming sufficient funding

Key Points: 
  • Company to initiate multi-national, multi-site pivotal study for Vitargus in 2020, assuming sufficient funding
    FREMONT, CA, Oct. 10, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American BriVision (Holding) Corporation (OTCQB: ABVC) (the Company), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that feasibility study results regarding Vitargus, its investigational medical device, will be reported during a presentation at the Retina Subspecialty Day program of the American Academy of Ophthalmology (AAO) 2019 Annual Meeting.
  • Given the encouraging study results, the Company plans to initiate a multi-national, multi-site pivotal study for Vitargus in 2020, assuming sufficient funding.
  • Vitargus is an injectable hydrogel that transforms into a gel matrix in the eye after injection and upon exposure to physiological temperatures.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.